|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lalonde E, Ishkanian AS, Sykes J, Fraser
M, Ross-Adams H, Erho N, Dunning MJ, Halim S, Lamb AD, Moon NC, et
al: Tumour genomic and microenvironmental heterogeneity for
integrated prediction of 5-year biochemical recurrence of prostate
cancer: A retrospective cohort study. Lancet Oncol. 15:1521–1532.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Van den Broeck T, van den Bergh RCN, Arfi
N, Gross T, Moris L, Briers E, Cumberbatch M, De Santis M, Tilki D,
Fanti S, et al: Prognostic value of biochemical recurrence
following treatment with curative intent for prostate cancer: A
systematic review. Eur Urol. 75:967–987. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Brockman JA, Alanee S, Vickers AJ,
Scardino PT, Wood DP, Kibel AS, Lin DW, Bianco FJ Jr, Rabah DM,
Klein EA, et al: Nomogram predicting prostate cancer-specific
mortality for men with biochemical recurrence after radical
prostatectomy. Eur Urol. 67:1160–1167. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fraser M, Berlin A, Bristow RG and van der
Kwast T: Genomic, pathological, and clinical heterogeneity as
drivers of personalized medicine in prostate cancer. Urol Onco.
33:85–94. 2015. View Article : Google Scholar
|
|
7
|
Burke HB: Predicting clinical outcomes
using molecular biomarkers. Biomark Cancer. 8:89–99. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Amaro A, Esposito AI, Gallina A, Nees M,
Angelini G, Albini A and Pfeffer U: Validation of proposed prostate
cancer biomarkers with gene expression data: A long road to travel.
Cancer Metastasis Rev. 33:657–671. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gleason DF and Mellinger GT: Prediction of
prognosis for prostatic adenocarcinoma by combined histological
grading and clinical staging. J Urol. 111:58–64. 1974. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ross HM, Kryvenko ON, Cowan JE, Simko JP,
Wheeler TM and Epstein JI: Do adenocarcinomas of the prostate with
Gleason score (GS) </=6 have the potential to metastasize to
lymph nodes? Am J Surg Pathol. 36:1346–1352. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Epstein JI, Zelefsky MJ, Sjoberg DD,
Nelson JB, Egevad L, Magi-Galluzzi C, Vickers AJ, Parwani AV,
Reuter VE, Fine SW, et al: A contemporary prostate cancer grading
system: A validated alternative to the gleason score. Eur Urol.
69:428–435. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Esserman LJ, Thompson IM, Reid B, Nelson
P, Ransohoff DF, Welch HG, Hwang S, Berry DA, Kinzler KW, Black WC,
et al: Addressing overdiagnosis and overtreatment in cancer: A
prescription for change. Lancet Oncol. 15:e234–e242. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yin Y, Zhang Q, Zhang H, He Y and Huang J:
Molecular signature to risk-stratify prostate cancer of
intermediate risk. Clin Cancer Res. 23:6–8. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Beauval JB, Roumiguié M, Filleron T,
Benoit T, de la Taille A, Malavaud B, Salomon L, Soulié M and
Ploussard G: Biochemical recurrence-free survival and pathological
outcomes after radical prostatectomy for high-risk prostate cancer.
BMC Urol. 16:262016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gearman DJ, Morlacco A, Cheville JC,
Rangel LJ and Karnes RJ: Comparison of pathological and oncologic
outcomes of favorable risk gleason score 3 + 4 and low risk gleason
score 6 prostate cancer: Considerations for active surveillance. J
Urol. 199:1188–1195. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mohler JL, Antonarakis ES, Armstrong AJ,
D'Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington TA,
Higano CS, et al: Prostate cancer, version 2.2019, NCCN clinical
practice guidelines in oncology. J Natl Compr Canc Netw.
17:479–505. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kaneko S, Hirakawa A and Hamada C:
Enhancing the lasso approach for developing a survival prediction
model based on gene expression data. Comput Math Methods Med.
2015:2594742015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pencina MJ, D'Agostino RB Sr and
Steyerberg EW: Extensions of net reclassification improvement
calculations to measure usefulness of new biomarkers. Stat Med.
30:11–21. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Abou-Ouf H, Alshalalfa M, Takhar M, Erho
N, Donnelly B, Davicioni E, Karnes RJ and Bismar TA: Validation of
a 10-gene molecular signature for predicting biochemical recurrence
and clinical metastasis in localized prostate cancer. J Cancer Res
Clin Oncol. 144:883–891. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Luo WM, Wang ZY and Zhang X:
Identification of four differentially methylated genes as
prognostic signatures for stage I lung adenocarcinoma. Cancer Cell
Int. 18:602018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yao Z, Sun B, Hong Q, Yan J, Mu D, Li J,
Sheng H and Guo H: The role of tumor suppressor gene SOX11 in
prostate cancer. Tumour Biol. 36:6133–6138. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hirschfield H, Bian CB, Higashi T,
Nakagawa S, Zeleke TZ, Nair VD, Fuchs BC and Hoshida Y: In vitro
modeling of hepatocellular carcinoma molecular subtypes for
anti-cancer drug assessment. Exp Mol Med. 50:e4192018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ninomiya T, Mihara K, Fushimi K, Hayashi
Y, Hashimoto-Tamaoki T and Tamaoki T: Regulation of the
alpha-fetoprotein gene by the isoforms of ATBF1 transcription
factor in human hepatoma. Hepatology. 35:82–87. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sun X, Frierson HF, Chen C, Li C, Ran Q,
Otto KB, Cantarel BL, Vessella RL, Gao AC, Petros J, et al:
Frequent somatic mutations of the transcription factor ATBF1 in
human prostate cancer. Nat Genet. 37:407–412. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pardo LA and Stühmer W: The roles of K(+)
channels in cancer. Nat Rev Cancer. 14:39–48. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ren KW, Li YH, Wu G, Ren JZ, Lu HB, Li ZM
and Han XW: Quercetin nanoparticles display antitumor activity via
proliferation inhibition and apoptosis induction in liver cancer
cells. Int J Oncol. 50:1299–1311. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu H and Zhang J: Decreased expression of
TFAP2B in endometrial cancer predicts poor prognosis: A study based
on TCGA data. Gynecol Oncol. 149:592–597. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gómez HL, Felipe-Medina N, Sánchez-Martin
M, Davies OR, Ramos I, García-Tuñón I, de Rooij DG, Dereli I, Tóth
A, Benavente R, et al: C14ORF39/SIX6OS1 is a constituent of the
synaptonemal complex and is essential for mouse fertility. Nat
Commun. 7:132982016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Taguchi A, Taylor AD, Rodriguez J,
Çeliktaş M, Liu H, Ma X, Zhang Z, Wong CH, Chin H, Girard L, et al:
A search for novel cancer/testis antigens in lung cancer identifies
VCX/Y genes, expanding the repertoire of potential
immunotherapeutic targets. Cancer Res. 74:4694–4705. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Geng Y, Ferreira JJ, Dzikunu V, Butler A,
Lybaert P, Yuan P, Magleby KL, Salkoff L and Santi CM: A genetic
variant of the sperm-specific SLO3 K+ channel has
altered pH and Ca2+ sensitivities. J Biol Chem.
292:8978–8987. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shukla KK, Mahdi AA and Rajender S: Ion
channels in sperm physiology and male fertility and infertility. J
Androl. 33:777–788. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bossini-Castillo L, de Kovel C, Kallberg
H, van 't Slot R, Italiaander A, Coenen M, Tak PP, Posthumus MD,
Wijmenga C, Huizinga T, et al: A genome-wide association study of
rheumatoid arthritis without antibodies against citrullinated
peptides. Ann Rheum Dis. 74:e152015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hauptman N, Jevšinek Skok D, Spasovska E,
Boštjančič E and Glavač D: Genes CEP55, FOXD3, FOXF2, GNAO1, GRIA4,
and KCNA5 as potential diagnostic biomarkers in colorectal cancer.
BMC Med Genomics. 12:542019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Barault L, Amatu A, Siravegna G, Ponzetti
A, Moran S, Cassingena A, Mussolin B, Falcomatà C, Binder AM,
Cristiano C, et al: Discovery of methylated circulating DNA
biomarkers for comprehensive non-invasive monitoring of treatment
response in metastatic colorectal cancer. Gut. 67:1995–2005. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Born G, Breuer D, Wang S, Rohlmann A,
Coulon P, Vakili P, Reissner C, Kiefer F, Heine M, Pape HC and
Missler M: Modulation of synaptic function through the
alpha-neurexin-specific ligand neurexophilin-1. Proc Natl Acad Sci
USA. 111:E1274–E1283. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Faryna M, Konermann C, Aulmann S, Bermejo
JL, Brugger M, Diederichs S, Rom J, Weichenhan D, Claus R, Rehli M,
et al: Genome-wide methylation screen in low-grade breast cancer
identifies novel epigenetically altered genes as potential
biomarkers for tumor diagnosis. FASEB J. 26:4937–4950. 2012.
View Article : Google Scholar : PubMed/NCBI
|
